Changeflow GovPing Pharma & Drug Safety Bumetanide Derivatives for Hyperhidrosis Therap...
Routine Notice Added Final

Bumetanide Derivatives for Hyperhidrosis Therapy - Otolanum AG

Favicon for changeflow.com EPO Patent Bulletin - Therapeutics (A61P)
Published
Detected
Email

Summary

EPO published patent application EP3774763A1 for bumetanide derivatives used in hyperhidrosis therapy. The patent, assigned to Otolanum AG with inventors Thomas Erker and Philipp Schreppel, covers pharmaceutical compositions and methods of treatment. The patent is designated for all 31 European states including Germany, France, the United Kingdom, Italy, and Spain.

What changed

EPO published patent application EP3774763A1 for bumetanide derivatives intended for hyperhidrosis therapy. The patent application, filed by Otolanum AG with inventors Thomas Erker and Philipp Schreppel, covers pharmaceutical compositions comprising bumetanide derivatives for therapeutic use in treating excessive sweating.

For pharmaceutical manufacturers and biotech companies developing diuretic-based therapies, this patent publication establishes intellectual property rights in European markets. Generic drug manufacturers and R&D teams should conduct freedom-to-operate analyses to assess potential patent overlap with existing or planned product development programs.

What to do next

  1. Review patent claims for freedom to operate
  2. Monitor for updates

Archived snapshot

Apr 15, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

BUMETANIDE DERIVATIVES FOR THE THERAPY OF HYPERHIDROSIS

Publication EP3774763A1 Kind: A1 Apr 08, 2026

Applicants

Otolanum AG

Inventors

ERKER, Thomas, SCHREPPEL, Philipp

IPC Classifications

C07D 333/18 20060101AFI20191011BHEP C07D 333/34 20060101ALI20191011BHEP C07D 333/40 20060101ALI20191011BHEP C07D 233/84 20060101ALI20191011BHEP C07C 311/18 20060101ALI20191011BHEP C07D 235/08 20060101ALI20191011BHEP C07D 239/38 20060101ALI20191011BHEP C07D 239/80 20060101ALI20191011BHEP C07D 265/30 20060101ALI20191011BHEP C07D 207/09 20060101ALI20191011BHEP C07D 211/34 20060101ALI20191011BHEP C07D 213/34 20060101ALI20191011BHEP A61P 25/00 20060101ALI20191011BHEP A61K 31/445 20060101ALI20191011BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
EPO
Published
April 8th, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP3774763A1
Docket
EP3774763

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent examination IP licensing
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals Healthcare

Get alerts for this source

We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!